Kidney Disease
Pegunigalsidase alfa treatment for Fabry disease achieves safety, efficacy goals
Malnutrition risk correlates with kidney function decline, CKD among older adults
Malnutrition is associated with poor kidney function, increased risk of kidney function decline and chronic kidney disease among older adults without advanced kidney disease, according to data published in the Journal of Renal Nutrition.
Jardiance phase 3 trial shows efficacy in patients with CKD, trial will stop early
The EMPA-Kidney trial will stop early due to evidence of Jardiance’s positive efficacy among patients with chronic kidney disease, according to a press release.
On World Kidney Day, efforts are underway to improve detection of CKD
Today is World Kidney Day, and the National Kidney Foundation is emphasizing its effort with the Coalition for Kidney Health to nominate targeted screening or case finding for chronic kidney disease based on risk conditions, like diabetes.
Q&A: AKI, CKD prevalence in transgender patients
AKI and chronic kidney disease prevalence is high among transgender patients, but this is rarely researched, according to a cross-sectional study published in the Clinical Journal of the American Society of Nephrology.
eGFR, urine output linked with lack of kidney recovery among ICU patients with COVID-19
A lower baseline eGFR and reduced urine output at the start of kidney replacement therapy “are strongly and independently” correlated with lack of kidney recovery among critically ill patients with COVID-19.
FDA: More studies needed to show bardoxolone reduces risk for ESKD
The FDA has told Reata Pharmaceuticals Inc. that it needs to conduct further studies to show its treatment for Alport syndrome is effective in slowing the progression of kidney disease, according to a company press release.
AKF launches campaign to involve underrepresented groups in kidney disease clinical trials
The American Kidney Fund announced a new campaign focused on encouraging “communities of color” to participate in kidney disease clinical trials.
Composite end point can be useful in future CKD progression studies
A composite end point that includes low eGFR, declining eGFR and kidney replacement therapy proved to be useful when studying chronic kidney disease progression, according to data published in Kidney Medicine.